- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Report
- December 2019
- 139 Pages
United States
From €2883EUR$3,000USD£2,464GBP
- Report
- January 2022
- 110 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- July 2022
- 100 Pages
Global
From €2642EUR$2,750USD£2,259GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Drug Pipelines
- September 2020
- 50 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- January 2024
- 90 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- May 2022
- 56 Pages
Global
From €1922EUR$2,000USD£1,643GBP
The Pleural Effusion Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pleural effusions, which are collections of fluid in the pleural cavity. These drugs are used to reduce the amount of fluid in the pleural cavity, reduce inflammation, and improve breathing. Commonly used drugs include diuretics, antibiotics, and corticosteroids. Other treatments, such as pleurodesis, may also be used.
The Pleural Effusion Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, and Sanofi. Other companies, such as Novartis, Boehringer Ingelheim, and Daiichi Sankyo, also offer drugs for the treatment of pleural effusions. Show Less Read more
